Search Articles
PHILADELPHIA – Blue Cross Blue Shield claims GlaxoSmithKline keeps its $1.3 billion annual monopoly on Wellbutrin SR (bupropion) through “fraudulent statements to patent examiners” and “filing baseless patent infringement actions” against generic manufacturers.
Categories /
Uncategorized
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.